Latest Safety News

Myer Holdings reported a 13.8% revenue increase in FY25, boosted by its acquisition of Apparel Brands, yet faced a statutory net loss of $211.2 million due to goodwill impairment. The integration of Apparel Brands is underway, with strategic growth initiatives in motion.

The European Medicines Agency has approved continuous bi-monthly dosing of CLINUVEL’s SCENESSE® for adult erythropoietic protoporphyria patients, removing previous annual dose limits and aligning Europe with US treatment standards.

INOVIQ Limited has demonstrated that its CAR-NK-exosome therapy kills over 90% of triple-negative breast cancer cells within 10 hours in laboratory tests, validating its potential as a next-generation cancer treatment.

Emyria secures a multi-year funding agreement with Medibank to support its Treatment-Resistant Depression program, marking a first for insurer-backed psychotherapy in Australia.

Lakes Blue Energy reports strong gas shows at its Wombat-5 well in Victoria’s Gippsland Basin, reinforcing hopes for a commercially viable gas development.

X2M Connect has secured a significant contract to digitise water meters for 6,750 Seoul households, marking a key step in the city's ambitious A$240 million smart metering initiative.

CLINUVEL Pharmaceuticals has presented compelling new case studies demonstrating the efficacy of SCENESSE® in treating vitiligo, showing significant and stable repigmentation in patients. These findings, shared at the EADV conference, hint at a potential breakthrough for a condition with limited treatment options.

PARKD Limited has clinched exclusive national rights to prefabricate key modular building components from Fielders, positioning itself to capitalize on booming construction sectors like data centres and self-storage across Australia.

OncoSil Medical’s PANCOSIL Phase 1-2 study reveals promising safety and feasibility for a novel CT-guided pancreatic cancer therapy, with survival outcomes exceeding historical benchmarks.

Imricor Medical Systems has successfully completed a comprehensive Human Factors study for all its devices under FDA review, marking a critical milestone towards U.S. market entry. The extensive 7-month study involved 46 healthcare professionals and tested nine products, underscoring Imricor’s growing momentum in electrophysiology innovation.

Larvotto Resources has officially begun upgrading its Hillgrove processing plant in New South Wales, aiming for mid-2026 completion and a significant increase in antimony and gold production.

WestStar Industrial’s subsidiary SIMPEC has landed a significant $8 million contract to supply and install ventilation systems for the NSW Government’s Western Harbour Tunnel, marking a strategic expansion into Sydney’s infrastructure sector.